Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin - PubMed

Affiliations

• PMID: 19598262
• DOI: 10.1002/ijc.24587

Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin

Ayako Kim et al. Int J Cancer. 2009.

Abstract

Clear cell carcinoma (CCC) of the ovary is known to be highly resistant to platinum-based chemotherapy. The purpose of our study was to identify a candidate protein that is associated with chemoresistance of CCC and to investigate the specific mechanism of chemoresistance conferred by the identified protein. Enhanced expression of Annexin A4 (Anx A4) was identified in ovarian CCC cells using 2-D differential gel electrophoresis (2D-DIGE) and mass spectrometry. Anx A4 levels were elevated in CCC cells compared with non-CCC cells as determined by real-time RT-PCR and Western blot analysis. Immunohistochemical analysis of Anx A4 was performed in 126 epithelial ovarian cancer tissue samples and demonstrated significantly elevated levels of Anx A4 protein levels in ovarian CCC tumors compared with ovarian serous and endometrioid tumors (p < 0.01). Anx A4-transfected ovarian non-CCC cells were more resistant to carboplatin (IC50 = 42 microM) compared with control cells (IC50 = 23 microM) as determined by modified MTT assay. Intracellular platinum levels were significantly lower in Anx A4-transfected cells compared with control cells after carboplatin treatment (p = 0.0020) and after an additional 360 min of carboplatin-free incubation (p = 0.0004), as measured by atomic absorption spectrophotometry. Expression of Anx A4 is elevated in ovarian CCC tumors and is associated with chemoresistance in cultured ovarian cancer cells. These results demonstrate that Anx A4 confers chemoresistance in ovarian cancer cells in part by enhancing drug efflux. Thus, Anx A4 may represent a novel therapeutic target of chemoresistance in patients with ovarian CCC.

Similar articles

• Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.

  Kim A, Serada S, Enomoto T, Naka T. Kim A, et al. Expert Opin Ther Targets. 2010 Sep;14(9):963-71. doi: 10.1517/14728222.2010.511180. Expert Opin Ther Targets. 2010. PMID: 20673185 Review.

• Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.

  Matsuzaki S, Serada S, Morimoto A, Ueda Y, Yoshino K, Kimura T, Naka T. Matsuzaki S, et al. Expert Opin Ther Targets. 2014 Apr;18(4):403-14. doi: 10.1517/14728222.2014.882323. Epub 2014 Jan 30. Expert Opin Ther Targets. 2014. PMID: 24479491 Review.

• Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.

  Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T. Matsuzaki S, et al. Int J Cancer. 2014 Apr 15;134(8):1796-809. doi: 10.1002/ijc.28526. Epub 2013 Oct 21. Int J Cancer. 2014. PMID: 24150977

• Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.

  Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z. Takaya A, et al. Int J Oncol. 2015 Apr;46(4):1573-81. doi: 10.3892/ijo.2015.2858. Epub 2015 Jan 28. Int J Oncol. 2015. PMID: 25633807

• Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.

  Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, Kim J, Kim TJ, Lee JW, Bae DS, Kim BG. Choi CH, et al. Hum Pathol. 2013 Jun;44(6):1017-23. doi: 10.1016/j.humpath.2012.08.024. Epub 2013 Jan 3. Hum Pathol. 2013. PMID: 23290009

Cited by

• Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.

  Mabuchi S, Sugiyama T, Kimura T. Mabuchi S, et al. J Gynecol Oncol. 2016 May;27(3):e31. doi: 10.3802/jgo.2016.27.e31. J Gynecol Oncol. 2016. PMID: 27029752 Free PMC article. Review.

• Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays.

  Lin LL, Huang HC, Juan HF. Lin LL, et al. PLoS One. 2012;7(9):e44615. doi: 10.1371/journal.pone.0044615. Epub 2012 Sep 7. PLoS One. 2012. PMID: 22970268 Free PMC article.

• Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.

  Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T, Naka T. Morimoto A, et al. Oncotarget. 2014 Sep 15;5(17):7776-87. doi: 10.18632/oncotarget.2306. Oncotarget. 2014. PMID: 25277200 Free PMC article.

• The Fhit protein: an opportunity to overcome chemoresistance.

  Gaudio E, Paduano F, Croce CM, Trapasso F. Gaudio E, et al. Aging (Albany NY). 2016 Nov 12;8(11):3147-3150. doi: 10.18632/aging.101123. Aging (Albany NY). 2016. PMID: 27852977 Free PMC article. No abstract available.

• Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma.

  Saad ZM, Fouad Y, Ali LH, Hassanin TM. Saad ZM, et al. Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2661-2665. doi: 10.31557/APJCP.2020.21.9.2661. Asian Pac J Cancer Prev. 2020. PMID: 32986366 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information